Linda Stocum, Associate Editor

ICYMI, some of this week’s featured content includes an exclusive interview about the iPLEDGE program issues, and articles on FDA approval of upadacitinib for psoriatic arthritis, ruxolitinib cream receiving Priority Review from the FDA for vitiligo, and more.

A recent study evaluated reflective confocal microscopy for actinic keratosis treated with 5-aminolevulinic acid photodynamic therapy.

A study investigated pulsed dye laser-mediated photodynamic therapy compared to conventional PDT for actinic keratosis.

John Barbieri, MD, MBA, FAAD, speaking in his capacity as a member of the AADA iPLEDGE Workgroup, talks with Dermatology Times® about the recent iPLEDGE website struggles and guidance on how dermatologists should handle the situation.

A recent study investigated practical issues related to the use of dupilumab for atopic dermatitis.

Klint Peebles, MD, FAAD, co-chair of the AAD LGBTQ/SGM Expert Resource Group, sits down with Dermatology Times® to discuss what changes were made to the iPLEDGE platform, examples of how the roll out has been unsuccessful, and how patients should be wary of trying to take old medications.

A study in JAMA Dermatology dove into the subject of atopic eczema, investigating the patterns of activity that may continue into adulthood.

In this video interview, Klint Peebles, MD, FAAD, co-chair of the AAD LGBTQ/SGM Expert Resource Group, explains what happened with the iPLEDGE website.

Verrica Pharmaceuticals announced the FDA acceptance of the New Drug Application (NDA) resubmission for VP-102 (Verrica Pharmaceuticals) for the treatment of molluscum contagiosum.

The FDA grants Priority Review for spesolimab (BI655130; Boehringer Ingelheim) as a treatment for generalized pustular psoriasis.

The FDA approves upadacitinib (Rinvoq; AbbVie) for the treatment of adult patients with active psoriatic arthritis.

Ruxolitinib cream (Opzelura; Incyte) receives priority review of its supplemental New Drug Application as a treatment for patients with vitiligo.

Physicians and their teams have been unable to access the iPLEDGE site during an update to incorporate an FDA-approved modification to the iPLEDGE REMS that took effect December 13, 2021.

A study investigated the acceptability and validity of patient-reported outcome measures for adult acne, comparing them to the validated acne-specific quality-of-life measure.

Arcutis Biotherapeutics has announced data suggesting that the vehicle in the investigational roflumilast cream had similar moisturizing properties as a commercially marketed, dermatologist-recommended, ceramide-containing moisturizer in adults with mild eczema.

This week's edition of the Mainstream Patients features stories about how to identify acne types, how to protect skin during the winter, and more.

This letter to the editor in the Journal of the American Academy of Dermatology investigated how mental health and its association to race and ethnicity relate to patients with acne.

ICYMI, some of this week’s featured content includes an exclusive interview about the unmet needs of vitiligo patients, and articles on international impetigo guidelines, the newly released tapinarof data, and more.

Here is what to expect from the “Getting to the Roots of Childhood Acne” live virtual webinar happening December 15 at 6:30 p.m.

A recent systematic review of guidelines of the management of impetigo was published in the Family Practice Journal.

Impetigo is a common skin infection in which ozenoxacin may be used as a treatment. This study aimed to evaluate the safety and efficacy of the therapy in pediatric patients compared to other topical treatments.

The New England Journal of Medicine has published the clinical trial data from the PSOARING 1 and PSOARING 2 studies on tapinarof treatment for plaque psoriasis.

This week’s edition of The Mainstream Patient features stories about a diet to manage psoriasis symptoms, face steaming, and more.

ICYMI, some of this week’s featured content includes an exclusive interview about the clinical implications of JAK inhibitors, and articles on trending skincare, Galderma, and more.

In this week's podcast, we sit down with from the OJM Group to discuss qualified retirement plans and how dermatology practices may be able to save money.

Galderma announced it has signed a definitive agreement to acquire ALASTIN Skincare.

Each month, Dermatology Times® features a roundup of products trending in skin care. Click here to find out what products are trending for the month of November.

This week’s edition of The Mainstream Patient features stories about probiotic skincare, how to manage dry skin, and more.

ICYMI, some of this week’s featured content includes an exclusive interview the science behind JAK inhibitors, and articles on the financial burden of wound care, the Procter and Gamble voluntary recall, and more.

Research aimed to understand how using daily skin care such as a mild cleanser and moisturizer impacts skin health.